Dr. Kim is currently the Virginia and D.K. Ludwig Professor of Biochemistry at Stanford University, Institute Scholar at Stanford ChEM-H and Lead Investigator of the Infectious Disease Initiative at the Chan Zuckerberg Biohub.
Dr. Kim was president of Merck Research Laboratories from 2003 to 2013, where he oversaw Merck's global drug and vaccine research and development activities.
During his tenure at MRL, Dr. Kim oversaw the approval of more than 20 new medicines and vaccines.
Prior to his time at Merck, Dr. Kim was a Professor of Biology at Massachusetts Institute of Technology and a Member of the Whitehead Institute where he conducted seminal research elucidating the way in which proteins enable viral membranes to fuse with cells.
Dr. Kim's exceptional record of scientific achievement resulted in his election to the National Academy of Sciences, the National Academy of Medicine, the National Academy of Engineering, the American Academy of Arts and Sciences and the Korean Academy of Science and Technology.
Dr. Kim is also a Fellow with the American Association for the Advancement of Science, the American Academy of Microbiology and the Biophysical Society.
Avidity Biosciences names new Directors
Indonesia's food and drugs regulator approves China's Sinovac COVID-19 with 65.3% efficacy
Maruho names new president and CEO
BioTheryX names new president and CEO
Clerics of Indonesia's Muslim council declare Sinovac's COVID-19 vaccine halal
Silver Named to TScan Therapeutics Board of Directors
Viking Therapeutics names new CFO and COO
European Commission Authorizes COVID-19 Vaccine Moderna in Europe
McMillan Named Chief Technical Officer at SwanBio Therapeutics
Jnana Therapeutics Names Chen to Board of Directors, Susztak to Scientific Advisory Board
Entrada Therapeutics Names Kim to its Board of Directors
Nuventra Pharma Sciences names new president
Nektar Therapeutics names interim chief medical officer, head of Development